Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4122952 | 0.94 | SIGMAR1 (0.54) | SIGMAR1ABL1KCNH2CNR1CNR2 | |
| SCHEMBL1356884 | 0.81 | SIGMAR1 (0.63) | SIGMAR1ABL1KCNH2 | |
| SCHEMBL1356458 | 0.78 | SIGMAR1 (0.59) | SIGMAR1ABL1KCNH2NOTUM | |
| SCHEMBL17965436 | 0.78 | SIGMAR1 (0.62) | SIGMAR1ABL1KCNH2CNR1CNR2 | |
| SCHEMBL1356691 | 0.75 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL1354724 | 0.75 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL1356873 | 0.75 | SIGMAR1 (0.77) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL4122947 | 0.74 | SIGMAR1 (0.57) | SIGMAR1ABL1KCNH2CNR1CNR2 | |
| SCHEMBL12406900 | 0.74 | SIGMAR1 (0.65) | SIGMAR1ABL1KCNH2NOTUM | |
| SCHEMBL1355904 | 0.73 | SIGMAR1 (0.64) | SIGMAR1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | claimed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | claimed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | claimed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | claimed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | claimed |
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | disclosed |
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | disclosed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | disclosed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
| WO-2007098967-A2 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR.ESTEVE, S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885ABL1 452/4885KCNH2 639/4885 |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885ABL1 452/4885KCNH2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.